Could existing cancer drugs tackle rare tumors? new trial aims to find out
NCT ID NCT07440290
First seen Feb 28, 2026 · Last updated Jun 19, 2026 · Updated 18 times
Summary
This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types. About 30 adults, children, and teenagers with BRAF V600-positive cancers will take the drugs daily. The goal is to see if tumors shrink or stop growing for at least 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Addenbrooke's Hospital
Cambridge, CB2 OQQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Alder Hey Hospital
Liverpool, L14 5AB, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belfast City Hospital
Belfast, BT9 7AB, United Kingdom
Contact Email: •••••@•••••
-
Birmingham Children's Hospital
Birmingham, B4 6NH, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Bristol Haematology and Oncology Centre
Bristol, BS2 8ED, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Bristol Royal Hospital for Children
Bristol, BS2 8BJ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cardiff Children's Hospital
Cardiff, CF14 4XW, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Churchill Hospital
Oxford, OX3 7LE, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clatterbridge Cancer Centre
Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Freeman Hospital
Newcastle, NE7 7DN, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Great North Children's Hospital
Newcastle, NE1 4LP, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guy's Hopsital
London, SE1 9RT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Radcliffe Hospital
Oxford, OX3 9DU, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Leicester Royal Infirmary
Leicester, LE1 5WW, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Hospital for Children Glasgow
Glasgow, G51 4TF, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Manchester Children's Hospital
Manchester, M13 9WL, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sheffield's Children's Hospital
Sheffield, S10 2TH, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southampton General Hospital
Southampton, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Beatson Hospital
Glasgow, G12 OYN, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Christie Hospital
Manchester, M20 4BX, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University College London Hospital
London, NW1 2BU, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Birmingham
Birmingham, B15 2TT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Velindre Cancer Centre
Cardiff, CF14 2TL, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weston Park Hospital
Sheffield, S10 2SJ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dabrafenib and trametinib (oral targeted therapy drugs)
What this could lead to
If successful, this could expand access to these drugs for people with rare cancers that have a BRAF V600 mutation, offering a new treatment option where few exist.
What could go wrong
This is an early-to-mid stage trial with only 30 participants, so results may not apply broadly. The drugs may not work for all cancer types, and side effects like fever, rash, or heart issues are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.